CoChat

NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression

Open access
Okayama, Hirokazu, Saito, Motonobu, Oue, Naohide, Weiss, Jonathan M., Stauffer, Jimmy, Takenoshita, Seiichi, Wiltrout, Robert H., Hussain, S. Perwez, Harris, Curtis C. · 2013 · International Journal of Cancer
Cited by 75

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Mutant KRAS in lung cancers induces molecular pathways that regulate cellular proliferation, survival and inflammation, which enhance tumorigenesis. Inducible nitric oxide synthase (NOS2) upregulation and sustained nitric oxide generation are induced during the inflammatory response and correlate positively with lung tumorigenesis. To explore the mechanistic contribution of NOS2 to KRAS‐induced lung tumorigenesis and inflammation, we used a genetic strategy of crossing NOS2 knockout (NOS2KO) C57BL6 inbred mice with a KRASG12D‐driven mouse lung cancer model. KRAS G12D;NOS2KO mice exhibited delayed lung tumorigenesis and a longer overall survival time compared to that of KRAS G12D;NOS2WT (wild‐type) controls. Correspondingly, tumors in KRAS G12D;NOS2KO mice had reduced tumor cell proliferation in adenomas and carcinomas. NOS2 deficiency also led to markedly suppressed inflammatory response by attenuation of macrophage recruitment into alveoli and within tumor foci. In contrast, FOXP3+ regulatory T cells were increased in tumors from KRAS G12D;NOS2KO mice. We further analyzed the expression of microRNA‐21 (miR‐21), an oncogenic noncoding RNA involved in oncogenic Ras signaling, by quantitative reverse‐transcription polymerase chain reaction and in situ hybridization. Lung carcinomas dissected from KRAS G12D;NOS2KO mice showed a significantly reduced miR‐21 expression along with decreased tumor cell proliferation, suggesting that NOS2 deficiency could attenuate RAS signaling pathways that transactivate miR‐21 expression. Therefore, deletion of NOS2 decreases lung tumor growth as well as inflammatory responses initiated by oncogenic KRAS, suggesting that both KRAS and NOS2 cooperate in driving lung tumorigenesis and inflammation. Inhibition of NOS2 may have a therapeutic value in lung cancers with oncogenic KRAS mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.27644

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 75

Metadata

Authors
Okayama, H., Saito, M., Oue, N., Weiss, J. M., Stauffer, J., Takenoshita, S., Wiltrout, R. H., Hussain, S. P., & Harris, C. C.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2012-06-13
Volume
132
Issue
1
Pages
9-18
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2036733146
Cited by
75
References
12
FWCI
2.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression. https://app.cochat.ai/papers/10.1002/ijc.27644
The paper
Okayama, H., Saito, M., Oue, N., Weiss, J. M., Stauffer, J., Takenoshita, S., Wiltrout, R. H., Hussain, S. P., & Harris, C. C. (2013). NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression. International Journal of Cancer. https://doi.org/10.1002/ijc.27644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.